Photosoft Platform Expands to Eye Diseases Via Partnership
Filed with ASX · · 4 pages · English
Summary by 6ix AI
Invion Ltd. has announced a partnership with SANGMYUNG Innovation to expand its Photosoft platform technology into the treatment of ocular diseases, specifically wet age-related macular degeneration. Under this collaboration, SANGMYUNG will fund and conduct preclinical studies using Photosoft compounds, while Invion retains all rights to the technology. The collaboration represents Invion's first venture into the ophthalmology space, highlighting the potential for broad applications of its Photosoft technology.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Earlier from Invion
- Appendix 4C and Quarterly Activities Report - March 2026
- Skin Cancer Trial Moves to BCC With More Encouraging Signals
- Appendix 4D and Half Year Financial Report
- Appendix 4C and Quarterly Activities Report - December 2025
- Major Shareholders Lead Invion $1.3M Capital Raise
Later from Invion
- Appendix 4C and Quarterly Activities Report - June 2026
- IVX Credentialed International Biotech Leader Joins Board
- Final Director's Interest Notice - Alistair Bennallack
- Initial Director's Interest Notice - Paul FIeld
- Appendix 4E and Annual Report
Follow Invion into a list and get an email when it puts out news.
Follow Invion